title: Binding of [3H]CB 34, a selective ligand for peripheral benzodiazepine receptors, to rat brain membranes.
abstract: The 2-phenyl-imidazo[1,2-a]pyridine derivative CB 34 is a ligand for peripheral benzodiazepine receptors. The binding of [3H]CB 34 to rat cerebrocortical membranes was characterized. Specific binding was rapid, reversible, saturable and of high affinity. Kinetic analysis yielded association and dissociation rate constants of 0.2x10(8) M(-1) min(-1) and 0.29 min(-1), respectively. Saturation binding experiments revealed a single class of binding sites with a total binding capacity of 188+/-8 fmol/mg protein and an apparent dissociation constant of 0.19+/-0.02 nM. Specific [3H]CB 34 binding was inhibited by ligands selective for peripheral benzodiazepine receptors, whereas, with the exception of flunitrazepam and diazepam, ligands for central benzodiazepine receptors were inactive. Of the brain regions examined, the density of the [3H]CB 34-binding sites was greatest in the hypothalamus and lowest in the cerebral cortex. [3H]CB 34 is thus a potent and selective ligand for peripheral benzodiazepine receptors and should be proven useful for studies of the roles of these receptors.
authors.affiliation: Chair of Pharmacology, Department of Experimental Biology "B. Loddo," University of Cagliari, 09100, Cagliari, Italy.
authors.forename: M G
authors.initials: MG
authors.lastname: Pisu
authors.forename: G
authors.initials: G
authors.lastname: Papi
authors.forename: P
authors.initials: P
authors.lastname: Porcu
authors.forename: G
authors.initials: G
authors.lastname: Trapani
authors.forename: A
authors.initials: A
authors.lastname: Latrofa
authors.forename: G
authors.initials: G
authors.lastname: Biggio
authors.forename: M
authors.initials: M
authors.lastname: Serra
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D001569:Benzodiazepines; D001570:Benzodiazepinones / Q000494:pharmacology; D001667:Binding, Competitive / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005442:Flumazenil / Q000494:pharmacology; D007093:Imidazoles / Q000378:metabolism* / Q000494:pharmacology; D007210:Indoleacetic Acids / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D008024:Ligands; D008565:Membrane Proteins / Q000187:drug effects / Q000378:metabolism; D008566:Membranes / Q000187:drug effects / Q000378:metabolism*; D003708:Nordazepam / Q000031:analogs & derivatives* / Q000494:pharmacology; D011725:Pyridines / Q000378:metabolism* / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011963:Receptors, GABA-A / Q000378:metabolism*; D014316:Tritium
chemical_list: D014151:Anti-Anxiety Agents; D001570:Benzodiazepinones; C120709:CB 34; D007093:Imidazoles; D007210:Indoleacetic Acids; D007546:Isoquinolines; D008024:Ligands; D008565:Membrane Proteins; D011725:Pyridines; D011963:Receptors, GABA-A; D014316:Tritium; D001569:Benzodiazepines; C081306:N,N-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide; C028513:4'-chlorodiazepam; D005442:Flumazenil; D003708:Nordazepam; C013434:chlordesmethyldiazepam; C037850:PK 11195